AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04768673
Drug: D501, D759, H053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
Trial: NCT05801380
Drug: AChE inhibitor monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a drug treatment using Donepezil only
Trial: NCT05801380
Drug: AChE inhibitor and NMDA receptor antagonist combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a drug treatment combining Donepezil and Memantine
Trial: NCT04043598
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Trial: NCT00501579
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04957550
Drug: SHR0302 tablets、Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 tablets dose 1 for 48 weeks
Trial: NCT04957550
Drug: SHR0302 tablets、Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 tablets dose 2 for 48 weeks
Trial: NCT04957550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
Trial: NCT05973097
Drug: total glucosides of paeony treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
Trial: NCT06546111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug :placebo tab PO BID for 14 days.
Trial: NCT06546111
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg tab PO BID for 14 days.
Trial: NCT05932862
Drug: XL309 (ISM3091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XL309 will be administered orally once daily.
Trial: NCT06335173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo
Trial: NCT05468138
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Trial: NCT00348244
Drug: Ketorolac, Prednisolone Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05399537
Drug: Prismocitrate 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
Trial: NCT04912466
Drug: Biological: IBI322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Trial: NCT05705414
Drug: Valine
RxNorm normalized name: Valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medical food intended for use under medical supervision
Trial: NCT05705414
Drug: EEA
RxNorm normalized name: BREEA SEGETA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A medical food intended for use under medical supervision
Trial: NCT06001112
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120mg
Trial: NCT06144814
Drug: Estrogen vaginal use form
RxNorm normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
Trial: NCT04234360
Drug: 5 days of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Trial: NCT06296212
Drug: TAD® 600 mg/4 mL powder and solvent for solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Trial: NCT05083468
Drug: SR750 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
Trial: NCT05083468
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
Trial: NCT06378125
Drug: Placebo controlled-ileal-release nicotinic acid (SAD/MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Trial: NCT06378125
Drug: Placebo immediate-release nicotinic acid (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Trial: NCT06509334
Drug: JYB1904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
Trial: NCT06509334
Drug: JYB1904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
Trial: NCT04886726
Drug: uhCG/EGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Trial: NCT06674109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo arm will take a placebo daily.
Trial: NCT05515809
Drug: Standard pain management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
Trial: NCT06709638
Drug: Zhilong Huoxue Tongyu capsule
RxNorm normalized name: ALCOHOL 42 mL in 60 mL TOPICAL GEL [TongYi CleanGuard Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhilong Huoxue Tongyu capsule
Trial: NCT06374771
Drug: Melatonin 10 MG
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg of Melatonin will be given orally pre and post-operative
Trial: NCT05237297
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg
Trial: NCT05237297
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg
Trial: NCT04542304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo for the 1-week study period.
Trial: NCT04963231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05860933
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00508768
Drug: Oral SCIO-469 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03205137
Drug: subjects treated with telmisartan/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects treated with telmisartan/hydrochlorothiazide
Trial: NCT03205137
Drug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
RxNorm normalized name: hydrochlorothiazide / telmisartan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Trial: NCT05324618
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
Trial: NCT05323110
Drug: CBS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
Trial: NCT05323110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS001 matched placebo
Trial: NCT06103188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill will be given to the patients 1 hour prior to their planned surgery.
Trial: NCT06103188
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin will be given to the patients 1 hour prior to their planned surgery.
Trial: NCT04558281
Drug: Placebo erector spinae plane perineural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administration via an erector spinae plane perineural catheter
Trial: NCT05300932
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Trial: NCT06344442
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
Trial: NCT05085964
Drug: RNA antisense oligonucleotide for intravitreal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject.
Trial: NCT04313972
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
Trial: NCT06598033
Drug: VC plus herbal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Trial: NCT06058078
Drug: RY_SW01 cell injection
RxNorm normalized name: phenylephrine tannate / pyrilamine tannate Oral Suspension [Ry-T-12]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Trial: NCT06058078
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for LN treatment
Trial: NCT05353985
Drug: TAK-062 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-062 placebo-matching tablets.
Trial: NCT06381726
Drug: Up-front Chemotherapy
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
Trial: NCT06681415
Drug: Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion.
Trial: NCT05146869
Drug: DBPR108 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
Trial: NCT05249790
Drug: Recommended treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Trial: NCT05249790
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Trial: NCT06684106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo together with statin in ASCVD patients
Trial: NCT05555589
Drug: RGN-259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
Trial: NCT05555589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
Trial: NCT06709885
Drug: CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
Trial: NCT06708767
Drug: Contrast Media
RxNorm normalized name: CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV contrast media administration
Trial: NCT06708767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT05376943
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
Trial: NCT05231668
Drug: SAR439459
RxNorm normalized name: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for solution for infusion; IV infusion
Trial: NCT05231668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion; IV infusion
Trial: NCT05785611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT05351801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06461286
Drug: PYC-001
RxNorm normalized name: PYCNANTHUS ANGOLENSIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Group Assignment
Trial: NCT00001128
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001128
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05068024
Drug: FWD1509 MsOH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
Trial: NCT05252078
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
Trial: NCT05174845
Drug: 1L PEG + ASCORBIC ACID
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid.
Trial: NCT05059587
Drug: MBA-P01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBA-P01 will be injected into the Glabellar line.
Trial: NCT06063772
Drug: Lactated Ringers, Intravenous
RxNorm normalized name: Lactated Ringers, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
Trial: NCT05022849
Drug: Bridging Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
Trial: NCT05053152
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06098079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
Trial: NCT06356311
Drug: Trifluridine-Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
Trial: NCT05464173
Drug: endocrinotherapy（doctor's choice）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the drug insert
Trial: NCT06356311
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Trial: NCT05000697
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
Trial: NCT00775476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
Trial: NCT04872218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 week treatment of IV placebo following recommended dosages from the abatacept monograph
Trial: NCT05483933
Drug: Pegylated Liposomal Doxorubicin + SL-172154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Trial: NCT03999853
Drug: BKR-017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKR-017
Trial: NCT05650242
Drug: BA1106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W).
Trial: NCT05555758
Drug: Adamgammadex Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aom0319 will be administered intravenously with water for injection.